Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)

Conditions:   Vaccine Reaction;   Vaccine Adverse Reaction Interventions:   Biological: Hepatitis B vaccine lot 1;   Biological: Hepatitis B vaccine lot 2;   Biological: Hepatitis B vaccine lot 3;   Biological: Hepatitis B vaccine (registered) Sponsors:   PT Bio Farma;   RS Umum Pusat Sanglah, Denpasar Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials